Availability of these MHC pentamer libraries makes using MHC multimers routinely for epitope screening and validation projects a realistic option for the first time
ProImmune has launched what it says is a unique MHC pentamer library product, called Prove.
Using a new rapid parallel synthesis process, ProImmune says it has been able to make sets of high quality MHC pentamers available at a much lower price per reagent than ever before.
The availability of these MHC pentamer libraries makes using MHC multimers routinely for epitope screening and validation projects a realistic option for the first time, the company says.
This opens up new applications for MHC multimer analysis and will bridge the gap between the screening of high numbers of T cell epitopes and the in-depth monitoring and characterisation of single specificity T cell immune responses.
Commenting on the launch of Prove, Nikolai Schwabe, CEO of ProImmune said: "We believe that introducing Prove MHC pentamer libraries addresses a real unmet need in the discovery and validation of important new disease targets for cancers, infectious diseases and in transplantation.
"This new product range complements our high end Pro5 MHC pentamers, which are typically used for in-depth study and monitoring of immune responses against validated antigens.
"The release of Prove marks another important milestone for ProImmune, setting us apart as a leader in product innovation in the immunology research field".
In many of areas of disease research that are centred on antigen activity, epitope analysis is a bottleneck step, limiting progress.
Prove MHC pentamer libraries will provide a novel approach for identifying candidate epitopes after mass screening has been completed.
This will allow rapid and conclusive validation of tens or even hundreds of high likelihood candidate antigens, thereby improving the entire epitope discovery processes significantly, says Promimmune.
Applications include research in the areas of cancer, infectious diseases or complications associated with transplantation, as well as monitoring the response to therapies such as new drugs and vaccines.
